Tomi Järvinen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Living Beings

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Huttunen Kristiina M; Mannila Anne; Laine Krista; Kemppainen Eeva; Leppänen Jukka; Vepsäläinen Jouko; Järvinen Tomi; Rautio Jarkko
The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.
Gynther Mikko; Ropponen Jarmo; Laine Krista; Leppänen Jukka; Haapakoski Paula; Peura Lauri; Järvinen Tomi; Rautio Jarkko
Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.
Matilainen Laura; Maunu Sirkka Liisa; Pajander Jari; Auriola Seppo; Jääskeläinen Ilpo; Larsen Kim Lambertsen; Järvinen Tomi; Jarho Pekka
The stability and dissolution properties of solid glucagon/gamma-cyclodextrin powder.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Tomi Järvinen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Huttunen Kristiina M; Mannila Anne; Laine Krista; Kemppainen Eeva; Leppänen Jukka; Vepsäläinen Jouko; Järvinen Tomi; Rautio Jarkko
The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.
Journal of medicinal chemistry 2009;52(14):4142-8.
2009: Gynther Mikko; Ropponen Jarmo; Laine Krista; Leppänen Jukka; Haapakoski Paula; Peura Lauri; Järvinen Tomi; Rautio Jarkko
Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.
Journal of medicinal chemistry 2009;52(10):3348-53.
2009: Matilainen Laura; Maunu Sirkka Liisa; Pajander Jari; Auriola Seppo; Jääskeläinen Ilpo; Larsen Kim Lambertsen; Järvinen Tomi; Jarho Pekka
The stability and dissolution properties of solid glucagon/gamma-cyclodextrin powder.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2009;36(4-5):412-20.
2008: Korjamo Timo; Holappa Jukka; Taimisto Sanna; Savolainen Jouko; Järvinen Tomi; Mönkkönen Jukka
Effect of N-betainate and N-piperazine derivatives of chitosan on the paracellular transport of mannitol in Caco-2 cells.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2008;35(3):226-34.
2008: Turunen Elina; Lehtonen Marko; Järvinen Tomi; Jarho Pekka
Development and validation of a gas chromatographic-mass spectrometric method for quantitative determination of perphenazine in rabbit plasma after sublingual administration.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;872(1-2):51-7.
2008: Kumpulainen Hanna; Järvinen Tomi; Mannila Anne; Leppänen Jukka; Nevalainen Tapio; Mäntylä Antti; Vepsäläinen Jouko; Rautio Jarkko
Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2008;34(2-3):110-7.
2008: Matilainen Laura; Larsen Kim Lambertsen; Wimmer Reinhard; Keski-Rahkonen Pekka; Auriola Seppo; Järvinen Tomi; Jarho Pekka
The effect of cyclodextrins on chemical and physical stability of glucagon and characterization of glucagon/gamma-CD inclusion complexes.
Journal of pharmaceutical sciences 2008;97(7):2720-9.
2008: Toropainen Tarja; Jarho Pekka; Lehtonen Marko; Keski-Rahkonen Pekka; Raatikainen Heli; Järvinen Tomi
Quantitative analysis of natural cyclodextrins by high-performance liquid chromatography with pulsed amperometric detection: application to cell permeation study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;867(1):90-8.
2008: Rautio Jarkko; Kumpulainen Hanna; Heimbach Tycho; Oliyai Reza; Oh Dooman; Järvinen Tomi; Savolainen Jouko
Prodrugs: design and clinical applications.
Nature reviews. Drug discovery 2008;7(3):255-70.
2008: Gynther Mikko; Laine Krista; Ropponen Jarmo; Leppänen Jukka; Mannila Anne; Nevalainen Tapio; Savolainen Jouko; Järvinen Tomi; Rautio Jarkko
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
Journal of medicinal chemistry 2008;51(4):932-6.
2008: Matilainen Laura; Toropainen Tarja; Vihola Henna; Hirvonen Jouni; Järvinen Tomi; Jarho Pekka; Järvinen Kristiina
In vitro toxicity and permeation of cyclodextrins in Calu-3 cells.
Journal of controlled release : official journal of the Controlled Release Society 2008;126(1):10-6.
2007: Garnier Tracy; Mäntylä Antti; Järvinen Tomi; Lawrence Jayne; Brown Marc; Croft Simon
In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
The Journal of antimicrobial chemotherapy 2007;60(4):802-10.
2007: Myllymäki Mikko J; Saario Susanna M; Kataja Antti O; Castillo-Melendez Joel A; Nevalainen Tapio; Juvonen Risto O; Järvinen Tomi; Koskinen Ari M P
Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
Journal of medicinal chemistry 2007;50(17):4236-42.
2007: Toropainen Tarja; Heikkilä Teemu; Leppänen Jukka; Matilainen Laura; Velaga Sitaram; Jarho Pekka; Carlfors Johan; Lehto Vesa-Pekka; Järvinen Tomi; Järvinen Kristiina
Crystal structure changes of gamma-cyclodextrin after the SEDS process in supercritical carbon dioxide affect the dissolution rate of complexed budesonide.
Pharmaceutical research 2007;24(6):1058-66.
2007: Kiviranta Päivi H; Leppänen Jukka; Rinne Valtteri M; Suuronen Tiina; Kyrylenko Olga; Kyrylenko Sergiy; Kuusisto Erkki; Tervo Anu J; Järvinen Tomi; Salminen Antero; Poso Antti; Wallén Erik A A
N-(3-(4-Hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors.
Bioorganic & medicinal chemistry letters 2007;17(9):2448-51.
2007: Huttunen Kristiina M; Mähönen Niina; Leppänen Jukka; Vepsäläinen Jouko; Juvonen Risto O; Raunio Hannu; Kumpulainen Hanna; Järvinen Tomi; Rautio Jarkko
Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.
Pharmaceutical research 2007;24(4):679-87.
2007: Mannila Janne; Järvinen Tomi; Järvinen Kristiina; Jarho Pekka
Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol.
Journal of pharmaceutical sciences 2007;96(2):312-9.
2007: Garnier Tracy; Mäntylä Antti; Järvinen Tomi; Lawrence M Jayne; Brown Marc B; Croft Simon L
Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.
The Journal of pharmacy and pharmacology 2007;59(1):41-9.
2007: Ribeiro Lina; Silva Nuno; Iley Jim; Rautio Jarkko; Järvinen Tomi; Mota-Filipe Hélder; Moreira Rui; Mendes Eduarda
Aminocarbonyloxymethyl ester prodrugs of flufenamic acid and diclofenac: suppressing the rearrangement pathway in aqueous media.
Archiv der Pharmazie 2007;340(1):32-40.
2006: Kiviranta Päivi H; Leppänen Jukka; Kyrylenko Sergiy; Salo Heikki S; Lahtela-Kakkonen Maija; Tervo Anu J; Wittekindt Carsten; Suuronen Tiina; Kuusisto Erkki; Järvinen Tomi; Salminen Antero; Poso Antti; Wallén Erik A A
N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors.
Journal of medicinal chemistry 2006;49(26):7907-11.
2006: Raitio Katri H; Savinainen Juha R; Nevalainen Tapio; Järvinen Tomi; Vepsäläinen Jouko
Synthesis and in vitro evaluation of novel 2-oxo-1,2-dihydroquinoline CB2 receptor inverse agonists.
Chemical biology & drug design 2006;68(6):334-40.
2006: Schwab Ursula S; Callaway James C; Erkkilä Arja T; Gynther Jukka; Uusitupa Matti I J; Järvinen Tomi
Effects of hempseed and flaxseed oils on the profile of serum lipids, serum total and lipoprotein lipid concentrations and haemostatic factors.
European journal of nutrition 2006;45(8):470-7.
2006: Jarho Elina M; Venäläinen Jarkko I; Juntunen Juha; Yli-Kokko A Leena; Vepsäläinen Jouko; Christiaans Johannes A M; Forsberg Markus M; Järvinen Tomi; Männistö Pekka T; Wallén Erik A A
An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors.
Bioorganic & medicinal chemistry letters 2006;16(21):5590-3.
2006: Toropainen Tarja; Velaga Sitaram; Heikkilä Teemu; Matilainen Laura; Jarho Pekka; Carlfors Johan; Lehto Vesa-Pekka; Järvinen Tomi; Järvinen Kristiina
Preparation of budesonide/gamma-cyclodextrin complexes in supercritical fluids with a novel SEDS method.
Journal of pharmaceutical sciences 2006;95(10):2235-45.
2006: Saario Susanna M; Palomäki Ville; Lehtonen Marko; Nevalainen Tapio; Järvinen Tomi; Laitinen Jarmo T
URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain.
Chemistry & biology 2006;13(8):811-4.
2006: Parkkari Teija; Savinainen Juha R; Raitio Katri H; Saario Susanna M; Matilainen Laura; Sirviö Tuomas; Laitinen Jarmo T; Nevalainen Tapio; Niemi Riku; Järvinen Tomi
Synthesis, cannabinoid receptor activity, and enzymatic stability of reversed amide derivatives of arachidonoyl ethanolamide.
Bioorganic & medicinal chemistry 2006;14(15):5252-8.
2006: Matilainen L; Järvinen K; Toropainen T; Näsi E; Auriola S; Järvinen T; Jarho P
In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A.
International journal of pharmaceutics 2006;318(1-2):41-8.
2006: Saario Susanna M; Poso Antti; Juvonen Risto O; Järvinen Tomi; Salo-Ahen Outi M H
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
Journal of medicinal chemistry 2006;49(15):4650-6.
2006: Parkkari Teija; Myllymäki Mikko; Savinainen Juha R; Saario Susanna M; Castillo-Meléndez Joel A; Laitinen Jarmo T; Nevalainen Tapio; Koskinen Ari M P; Järvinen Tomi
Alpha-methylated derivatives of 2-arachidonoyl glycerol: synthesis, CB1 receptor activity, and enzymatic stability.
Bioorganic & medicinal chemistry letters 2006;16(9):2437-40.
2006: Parkkari Teija; Salo Outi M H; Huttunen Kristiina M; Savinainen Juha R; Laitinen Jarmo T; Poso Antti; Nevalainen Tapio; Järvinen Tomi
Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE).
Bioorganic & medicinal chemistry 2006;14(8):2850-8.
2006: Raitio Katri H; Savinainen Juha R; Vepsäläinen Jouko; Laitinen Jarmo T; Poso Antti; Järvinen Tomi; Nevalainen Tapio
Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
Journal of medicinal chemistry 2006;49(6):2022-7.
2006: Mannila Janne; Järvinen Tomi; Järvinen Kristiina; Tervonen Jussi; Jarho Pekka
Sublingual administration of Delta9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Delta9-tetrahydrocannabinol in rabbits.
Life sciences 2006;78(17):1911-4.
2006: Holappa Jukka; Nevalainen Tapio; Soininen Pasi; Másson Már; Järvinen Tomi
Synthesis of novel quaternary chitosan derivatives via N-Chloroacyl-6-O-triphenylmethylchitosans.
Biomacromolecules 2006;7(2):407-10.
2006: Kumpulainen Hanna; Mähönen Niina; Laitinen Marja-Leena; Jaurakkajärvi Marja; Raunio Hannu; Juvonen Risto O; Vepsäläinen Jouko; Järvinen Tomi; Rautio Jarkko
Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
Journal of medicinal chemistry 2006;49(3):1207-11.
2006: Holappa Jukka; Nevalainen Tapio; Safin Rustam; Soininen Pasi; Asplund Tomas; Luttikhedde Tiina; Másson Már; Järvinen Tomi
Novel water-soluble quaternary piperazine derivatives of chitosan: synthesis and characterization.
Macromolecular bioscience 2006;6(2):139-44.
2006: Salo Outi M H; Savinainen Juha R; Parkkari Teija; Nevalainen Tapio; Lahtela-Kakkonen Maija; Gynther Jukka; Laitinen Jarmo T; Järvinen Tomi; Poso Antti
3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
Journal of medicinal chemistry 2006;49(2):554-66.
2006: Mannila Anne; Kokki Hannu; Heikkinen Marja; Laisalmi Merja; Lehtonen Marko; Louhisto Hanna L; Järvinen Tomi; Savolainen Jouko
Cerebrospinal fluid distribution of ketoprofen after intravenous administration in young children.
Clinical pharmacokinetics 2006;45(7):737-43.
2005: Salo Outi M H; Raitio Katri H; Savinainen Juha R; Nevalainen Tapio; Lahtela-Kakkonen Maija; Laitinen Jarmo T; Järvinen Tomi; Poso Antti
Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
Journal of medicinal chemistry 2005;48(23):7166-71.
2005: Kumpulainen Hanna; Järvinen Tomi; Saari Raimo; Lehtonen Marko; Vepsäläinen Jouko
An efficient strategy for the synthesis of 1-chloroethyl phosphates and phosphoramidates.
The Journal of organic chemistry 2005;70(22):9056-8.
2005: Juntunen Juha; Järvinen Tomi; Niemi Riku
In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs.
The Journal of pharmacy and pharmacology 2005;57(9):1153-7.
2005: Mannila Janne; Järvinen Tomi; Järvinen Kristiina; Tarvainen Maarit; Jarho Pekka
Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;26(1):71-7.
2005: Savinainen Juha R; Kokkola Tarja; Salo Outi M H; Poso Antti; Järvinen Tomi; Laitinen Jarmo T
Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.
British journal of pharmacology 2005;145(5):636-45.
2005: Saario Susanna M; Salo Outi M H; Nevalainen Tapio; Poso Antti; Laitinen Jarmo T; Järvinen Tomi; Niemi Riku
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes.
Chemistry & biology 2005;12(6):649-56.
2005: Niemi Riku; Huuskonen Juhani; Laine Krista; Järvinen Tomi
Synthesis, hydrolysis, and intraocular pressure lowering effects of fadolmidine prodrugs.
International journal of pharmaceutics 2005;295(1-2):121-7.
2005: Callaway James; Schwab Ursula; Harvima Ilkka; Halonen Pirjo; Mykkänen Otto; Hyvönen Pekka; Järvinen Tomi
Efficacy of dietary hempseed oil in patients with atopic dermatitis.
The Journal of dermatological treatment 2005;16(2):87-94.
2005: Loftsson Thorsteinn; Jarho Pekka; Másson Már; Järvinen Tomi
Cyclodextrins in drug delivery.
Expert opinion on drug delivery 2005;2(2):335-51.
2005: Holappa Jukka; Nevalainen Tapio; Soininen Pasi; Elomaa Matti; Safin Rustam; Másson Már; Järvinen Tomi
N-Chloroacyl-6-O-triphenylmethylchitosans: useful intermediates for synthetic modifications of chitosan.
Biomacromolecules 2005;6(2):858-63.
2005: Savolainen Jouko; Niemi Riku; Mäntylä Antti; Huuskonen Juhani; Järvinen Tomi
Fadolmidine-induced ocular hypotension in normotensive rabbits.
The Journal of pharmacy and pharmacology 2005;57(2):191-5.
2005: Mannila Anne; Rautio Jarkko; Lehtonen Marko; Järvinen Tomi; Savolainen Jouko
Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;24(1):101-5.
2005: Raitio K H; Salo O M H; Nevalainen T; Poso A; Järvinen T
Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.
Current medicinal chemistry 2005;12(10):1217-37.
2004: Tervo Anu J; Kyrylenko Sergiy; Niskanen Päivi; Salminen Antero; Leppänen Jukka; Nyrönen Tommi H; Järvinen Tomi; Poso Antti
An in silico approach to discovering novel inhibitors of human sirtuin type 2.
Journal of medicinal chemistry 2004;47(25):6292-8.
2004: Jarho Elina M; Venäläinen Jarkko I; Huuskonen Juhani; Christiaans Johannes A M; Garcia-Horsman J Arturo; Forsberg Markus M; Järvinen Tomi; Gynther Jukka; Männistö Pekka T; Wallén Erik A A
A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.
Journal of medicinal chemistry 2004;47(23):5605-7.
2004: Mäntylä Antti; Rautio Jarkko; Nevalainen Tapio; Keski-Rahkonen Pekka; Vepsälainen Jouko; Järvinen Tomi
Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2004;23(2):151-8.
2004: Mannila Janne; Lehtonen Marko; Järvinen Tomi; Jarho Pekka
Determination of Delta9-tetrahydrocannabinol from rabbit plasma by gas chromatography-mass spectrometry using two ionization techniques.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;810(2):283-90.
2004: Mäntylä Antti; Rautio Jarkko; Nevalainen Tapio; Vepsälainen Jouko; Juvonen Risto; Kendrick Howard; Garnier Tracy; Croft Simon L; Järvinen Tomi
Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.
Bioorganic & medicinal chemistry 2004;12(13):3497-502.
2004: Salo Outi M H; Lahtela-Kakkonen Maija; Gynther Jukka; Järvinen Tomi; Poso Antti
Development of a 3D model for the human cannabinoid CB1 receptor.
Journal of medicinal chemistry 2004;47(12):3048-57.
2004: Parkkari Teija; Savinainen Juha R; Rauhala Anu L; Tolonen Tiina L; Nevalainen Tapio; Laitinen Jarmo T; Gynther Jukka; Järvinen Tomi
Synthesis and CB1 receptor activities of novel arachidonyl alcohol derivatives.
Bioorganic & medicinal chemistry letters 2004;14(12):3231-4.
2004: Saario Susanna M; Savinainen Juha R; Laitinen Jarmo T; Järvinen Tomi; Niemi Riku
Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes.
Biochemical pharmacology 2004;67(7):1381-7.
2004: Mäntylä Antti; Garnier Tracy; Rautio Jarkko; Nevalainen Tapio; Vepsälainen Jouko; Koskinen Ari; Croft Simon L; Järvinen Tomi
Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone.
Journal of medicinal chemistry 2004;47(1):188-95.
2003: Savinainen Juha R; Saario Susanna M; Niemi Riku; Järvinen Tomi; Laitinen Jarmo T
An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
British journal of pharmacology 2003;140(8):1451-9.
2003: Juntunen Juha; Vepsäläinen Jouko; Niemi Riku; Laine Krista; Järvinen Tomi
Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether.
Journal of medicinal chemistry 2003;46(23):5083-6.
2003: Turhanen Petri A; Niemi Riku; Peräkylä Mikael; Järvinen Tomi; Vepsäläinen Jouko J
First synthesis of etidronate partial amides starting from PCl3.
Organic & biomolecular chemistry 2003;1(18):3223-6.
2003: Fowler Christopher J; Jonsson Kent-Olov; Andersson Anna; Juntunen Juha; Järvinen Tomi; Vandevoorde Séverine; Lambert Didier M; Jerman Jeffrey C; Smart Darren
Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid.
Biochemical pharmacology 2003;66(5):757-67.
2003: Savolainen Jouko; Rautio Jarkko; Razzetti Roberta; Järvinen Tomi
A novel D2-dopaminergic and alpha2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits.
The Journal of pharmacy and pharmacology 2003;55(6):789-94.
2003: Kinnarinen Tarja; Jarho Pekka; Järvinen Kristiina; Järvinen Tomi
Pulmonary deposition of a budesonide/gamma-cyclodextrin complex in vitro.
Journal of controlled release : official journal of the Controlled Release Society 2003;90(2):197-205.
2003: Juntunen Juha; Huuskonen Juhani; Laine Krista; Niemi Riku; Taipale Hannu; Nevalainen Tapio; Pate David W; Järvinen Tomi
Anandamide prodrugs. 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2003;19(1):37-43.
2003: Forsberg Markus; Lehtonen Marko; Heikkinen Minna; Savolainen Jouko; Järvinen Tomi; Männistö Pekka T
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
The Journal of pharmacology and experimental therapeutics 2003;304(2):498-506.
2003: Laine Krista; Järvinen Kristiina; Järvinen Tomi
Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits.
Life sciences 2003;72(7):837-42.
2002: Laine Krista; Järvinen Kristiina; Mechoulam Raphael; Breuer Aviva; Järvinen Tomi
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.
Investigative ophthalmology & visual science 2002;43(10):3216-22.
2002: Järvinen Tomi; Pate David W; Laine Krista
Cannabinoids in the treatment of glaucoma.
Pharmacology & therapeutics 2002;95(2):203-20.
2002: Forsberg Markus; Savolainen Jouko; Järvinen Tomi; Leppänen Jukka; Gynther Jukka; Männistö Pekka T
Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
Pharmacology & toxicology 2002;90(6):327-32.
2002: Leppänen Jukka; Huuskonen Juhani; Nevalainen Tapio; Gynther Jukka; Taipale Hannu; Järvinen Tomi
Design and synthesis of a novel L-dopa-entacapone codrug.
Journal of medicinal chemistry 2002;45(6):1379-82.
2002: Laine Krista; Järvinen Kristiina; Pate David W; Urtti Arto; Järvinen Tomi
Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides.
Investigative ophthalmology & visual science 2002;43(2):393-7.
2001: Leppänen J; Savolainen J; Nevalainen T; Forsberg M; Huuskonen J; Taipale H; Gynther J; Männistö P T; Järvinen T
Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
The Journal of pharmacy and pharmacology 2001;53(11):1489-98.
2001: Savinainen J R; Järvinen T; Laine K; Laitinen J T
Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes.
British journal of pharmacology 2001;134(3):664-72.
2001: Laine K; Järvinen T; Savinainen J; Laitinen J T; Pate D W; Järvinen K
Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits.
Pharmaceutical research 2001;18(4):494-9.
2001: Suihko E; Korhonen O; Järvinen T; Ketolainen J; Jarho P; Laine E; Paronen P
Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-beta-cyclodextrin.
International journal of pharmaceutics 2001;215(1-2):137-45.
2001: Raiman J; Niemi R; Vepsäläinen J; Yritys K; Järvinen T; Mönkkönen J
Effects of calcium and lipophilicity on transport of clodronate and its esters through Caco-2 cells.
International journal of pharmaceutics 2001;213(1-2):135-42.
2000: Leppänen J; Huuskonen J; Savolainen J; Nevalainen T; Taipale H; Vepsäläinen J; Gynther J; Järvinen T
Synthesis of a water-soluble prodrug of entacapone.
Bioorganic & medicinal chemistry letters 2000;10(17):1967-9.
2000: Niemi R; Turhanen P; Vepsäläinen J; Taipale H; Järvinen T
Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;11(2):173-80.
2000: Rautio J; Nevalainen T; Taipale H; Vepsäläinen J; Gynther J; Laine K; Järvinen T
Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;11(2):157-63.
2000: Rautio J; Nevalainen T; Taipale H; Vepsäläinen J; Gynther J; Laine K; Järvinen T
Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery.
Journal of medicinal chemistry 2000;43(8):1489-94.
1999: Niemi R; Vepsäläinen J; Taipale H and; Järvinen T
Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid.
Journal of medicinal chemistry 1999;42(24):5053-8.
1999: Rautio J; Nevalainen T; Taipale H; Vepsäläinen J; Gynther J; Pedersen T; Järvinen T
Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propionic acid as novel naproxen prodrugs for dermal drug delivery.
Pharmaceutical research 1999;16(8):1172-8.
1999: Ahlmark M; Vepsäläinen J; Taipale H; Niemi R; Järvinen T
Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate.
Journal of medicinal chemistry 1999;42(8):1473-6.
1998: Savolainen J; Järvinen K; Taipale H; Jarho P; Loftsson T; Järvinen T
Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms.
Pharmaceutical research 1998;15(11):1696-701.
1998: Saarinen-Savolainen P; Järvinen T; Araki-Sasaki K; Watanabe H; Urtti A
Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line.
Pharmaceutical research 1998;15(8):1275-80.
1998: Suhonen P; Järvinen T; Koivisto S; Urtti A
Different effects of pH on the permeation of pilocarpine and pilocarpine prodrugs across the isolated rabbit cornea.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1998;6(3):169-76.
1998: Jarho P; Pate D W; Brenneisen R; Järvinen T
Hydroxypropyl-beta-cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of delta9-tetrahydrocannabinol.
Life sciences 1998;63(26):PL381-4.
1998: Pate D W; Järvinen K; Urtti A; Mahadevan V; Järvinen T
Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits.
Life sciences 1998;63(24):2181-8.
1997: Pate D W; Järvinen K; Urtti A; Jarho P; Mahadevan V; Järvinen T
Effects of topical alpha-substituted anandamides on intraocular pressure in normotensive rabbits.
Pharmaceutical research 1997;14(12):1738-43.
1997: Niemi R; Taipale H; Ahlmark M; Vepsäläinen J; Järvinen T
Simultaneous determination of clodronate and its partial ester derivatives by ion-pair reversed-phase high-performance liquid chromatography coupled with evaporative light-scattering detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;701(1):97-102.
1997: Järvinen T; Rautio J; Niemi R
[Prodrugs]
Duodecim; lääketieteellinen aikakauskirja 1997;113(24):2564-8.
1996: Jarho P; Järvinen K; Urtti A; Stella V J; Järvinen T
Modified beta-cyclodextrin (SBE7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits.
The Journal of pharmacy and pharmacology 1996;48(3):263-9.
1996: Pate D W; Järvinen K; Urtti A; Jarho P; Fich M; Mahadevan V; Järvinen T
Effects of topical anandamides on intraocular pressure in normotensive rabbits.
Life sciences 1996;58(21):1849-60.
1996: Jarho P; Urtti A; Järvinen K; Pate D W; Järvinen T
Hydroxypropyl-beta-cyclodextrin increases aqueous solubility and stability of anandamide.
Life sciences 1996;58(10):PL 181-5.
1995: Kinonen T; Pasanen M; Gynther J; Poso A; Järvinen T; Alhava E; Juvonen R O
Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6.
British journal of pharmacology 1995;116(6):2625-30.
1995: Jarho P; Urtti A; Järvinen T
Hydroxypropyl-beta-cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrugs.
Pharmaceutical research 1995;12(9):1371-5.
1995: Pate D W; Järvinen K; Urtti A; Jarho P; Järvinen T
Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits.
Current eye research 1995;14(9):791-7.
1995: Järvinen T; Poikolainen M; Suhonen P; Vepsäläinen J; Alaranta S; Urtti A
Comparison of enzymatic hydrolysis of pilocarpine prodrugs in human plasma, rabbit cornea, and butyrylcholinesterase solutions.
Journal of pharmaceutical sciences 1995;84(5):656-60.
1995: Suhonen P; Järvinen T; Lehmussaari K; Reunamäki T; Urtti A
Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop.
Pharmaceutical research 1995;12(4):529-33.
1995: Järvinen T; Järvinen K; Schwarting N; Stella V J
beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs.
Journal of pharmaceutical sciences 1995;84(3):295-9.
1995: Järvinen T; Järvinen K; Urtti A; Thompson D; Stella V J
Sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1995;11(2):95-106.
1994: Järvinen K; Järvinen T; Thompson D O; Stella V J
The effect of a modified beta-cyclodextrin, SBE4-beta-CD, on the aqueous stability and ocular absorption of pilocarpine.
Current eye research 1994;13(12):897-905.
1992: Järvinen T; Suhonen P; Auriola S; Vepsäläinen J; Urtti A; Peura P
Synthesis and analysis of O,O'-dicarboxylate (dibenzyl) bispilocarpates as possible prodrugs of pilocarpine.
Journal of pharmaceutical and biomedical analysis 1992;10(2-3):153-61.
1991: Suhonen P; Järvinen T; Rytkönen P; Peura P; Urtti A
Improved corneal pilocarpine permeability with O,O'-(1,4-xylylene) bispilocarpic acid ester double prodrugs.
Pharmaceutical research 1991;8(12):1539-42.
1991: Järvinen T; Suhonen P; Naumanen H; Urtti A; Peura P
Determination of physicochemical properties, stability in aqueous solutions and serum hydrolysis of pilocarpic acid diesters.
Journal of pharmaceutical and biomedical analysis 1991;9(9):737-45.
1991: Järvinen T; Auriola S; Peura P; Suhonen P; Urtti A; Vepsäläinen J
Synthesis and identification of pilocarpic acid diesters, prodrugs of pilocarpine.
Journal of pharmaceutical and biomedical analysis 1991;9(6):457-64.
1989: Järvinen T; Keinonen T; Auriola S; Peura P; Hirvonen E; Palva E
Specific and sensitive quantitation of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry.
Journal of chromatography 1989;495():13-20.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Tomi Järvinen

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Living Beings

Phenomena

Genes & Molecular Sequences

Physiology

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Tomi Järvinen (preview)

All Publications